Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

The risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is and with GLP-1 RAs versus DPP-4is.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage, RNAi-based investigational therapeutics ...

Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

With the rising global obesity epidemic and the increasing demand for effective weight-loss treatments, the biopharma industry faces mounting pressure to revolutionize GLP-1 manufacturing to meet ...

Researchers from the University of Oxford have conducted a comprehensive overview of the potential benefits or harms of glucagon-like peptide-1 ... mechanisms and potential clinical uses of GLP ...

Bruce Springsteen — 11 Bruce Springsteen's 11 chart-topping albums span over three decades, from 1980's "The River" to 2014's "High Hopes" — even though Springsteen has yet to score a No. 1 ...

The success of our weight-loss specialty has been another key driver in the increase in monthly online revenue per average subscriber through two mechanisms ... of popular GLP-1 compounds.

GLP-1 receptor agonists are pharmaceutical treatments primarily for T2D and more recently, obesity. They function by mimicking the action of GLP-1 hormone, which plays a crucial role in ...

For instance, the review showed that GLP-1 drugs may have promising outcomes for people with dementia or other neurological disorders. “There is also evidence for mechanisms involving a ...